Risk factors for secondary glaucoma in children

Article

Risk factors for secondary glaucoma in children

For children with uveitis, juvenile idiopathic arthritis-associated uveitis and ANA-positive uveitis without evidence of arthritis are the most common risk factors for developing secondary glaucoma, according to the results of a study published in the May 2006 issue of Ophthalmology.

Karen M. Sijssens MD, and her colleagues from the FC Donders Institute of Ophthalmology, Utrecht, and the University Eye Clinic, Maastricht, The Netherlands, conducted a retrospective, observational case series of 256 eyes of 147 children diagnosed with uveitis before the age of 16.

The researchers were looking for localization and course of uveitis, underlying systemic disease, onset of ocular hypertension, onset of secondary glaucoma, treatment with steroids, antinuclear antibodies (ANAs), lens extractions, number of blind eyes at onset and during follow-up.

Elevated intraocular pressure (IOP) was recorded in 35% of subjects regardless of the form or type of uveitis. However, secondary glaucoma developed more frequently (38%) in juvenile idiopathic arthritis-associated uveitis compared with other forms of uveitis (11%). Secondary glaucoma was also observed more frequently in subjects who were ANA positive (42%) than those who were ANA negative (6%). Except for patients with juvenile idiopathic arthritis-associated uveitis, periocular steroid injections represented an additional risk factor for secondary glaucoma, limited to the early phases of the disease process.

The results suggest a strong link between juvenile idiopathic arthritis-associated uveitis, ANA-positive uveitis and secondary glaucoma.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.